Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

INTRODUCTION. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Vincenzi, Bruno, Santini, Daniele, Russo, Antonio, Addeo, Raffaele, Giuliani, Francesco, Montella, Liliana, Rizzo, Sergio, Venditti, Olga, Frezza, Anna Maria, Caraglia, Michele, Colucci, Giuseppe, Del Prete, Salvatore, Tonini, Giuseppe
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2010
Soggetti:
Hepatobiliary
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227883/
https://ncbi.nlm.nih.gov/pubmed/20051477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0143
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi